Loading
A phase 2 trial of Inotuzumab ozogamicin in acute lymphoblastic leukaemia, run by Pfizer, now recruiting.
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL is a phase 2 interventional study registered as NCT05748171 by Pfizer, with 100 participants planned, started 2023-05-17 and due to reach its primary completion in 2033-05-21. Interventions recorded: Inotuzumab ozogamicin and ALLR3.
Shares Relapsed and refractory acute lymphoblastic leukaemia in children, Acute lymphoblastic leukaemia and the tag pipeline.
Shares Pfizer (incl. Seagen), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Relapsed and refractory acute lymphoblastic leukaemia in children, Acute lymphoblastic leukaemia and the tag pipeline.
Shares Relapsed and refractory acute lymphoblastic leukaemia in children, Acute lymphoblastic leukaemia and the tag pipeline.
Shares Pfizer (incl. Seagen), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Relapsed and refractory acute lymphoblastic leukaemia in children, Acute lymphoblastic leukaemia and the tag pipeline.
Shares Pfizer (incl. Seagen), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Pfizer (incl. Seagen), Antibody-drug conjugate (ADC) and the tag pipeline.